Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Melanie Senior


London, UK

Experienced biopharmaceutical industry analyst, reporter & commentator following strategic, commercial and scientific issues affecting the sector. Regular contributor to Nature Biotechnology, Informa Business Intelligence (IN VIVO, Datamonitor, Scrip) and EY Life Sciences. Specialist & feature coverage and consulting across market access, pricing, outcomes-based care, precision medicine, digital health, AI, R&D strategies and consumer empowerment for a range of clients in biopharma and investment community.

Latest From Melanie Senior

Why US Payers Aren’t Reimbursing Obesity Meds

Payers are restricting access to obesity drugs due to huge patient numbers and a wave of innovation in other areas

Metabolic Disorders Market Access

Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy

Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”

Clinical Trials Innovation

The New Antibodies Revolutionizing Medicine

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

Innovation Research & Development

What Next In Oncology?

Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda? 

Cancer Innovation

Deals In 2023: Partnerships And Modest M&A

Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.

Growth Deals

On The Cusp: UK Biotech Verona Pharma Awaits Potential Blockbuster

Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.

Respiratory Clinical Trials
See All